Are chronic dialysis patients at increased risk for cancer?

Journal of Nephrology

Volumn 21, Issue 2, 2008, Pages 166-174

  Mandayam, Sreedhar ^a   Shahinian, Vahakn B ^b  

^a Wichita Nephrology Group   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Dialysis; Relative risk; Screening

Indexed keywords

ANALGESIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE;

BLADDER CARCINOMA; BREAST CANCER; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; COLON CANCER; COST EFFECTIVENESS ANALYSIS; DIALYSIS; DISEASE ASSOCIATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; LIFE EXPECTANCY; LIVER CANCER; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SKIN CANCER; UREMIA; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER; CHRONIC KIDNEY FAILURE; NEOPLASM; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; RISK FACTOR;

HUMANS; KIDNEY FAILURE, CHRONIC; NEOPLASMS; RENAL DIALYSIS; RISK FACTORS;

EID: 50049094617     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Doak PB, Montgomerie JZ, North JD, Smith F. Reticulum cell sarcoma after renal homotransplantations and azathioprine and prednisone. BMJ. 1968;4:746-768.
2. Kjellstrand CM. Are malignancies increased in uremia? Nephron. 1979;23:159-161.
3. Zeier M, Hartschuh W, Wiesel M, Lehnert T, Ritz E. Malignancy after renal transplantation. Am J Kidney Dis. 2002;39:1-12.
4. Marple JT, MacDougall M. Development of malignancy in the end-stage renal disease patient. Semin Nephrol. 1993;13:306-314.
5. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354:93-99.
6. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer before and after kidney transplantation. JAMA. 2006;296:2823-2831.
7. Heidland A, Bahner U, Vamvakas S. Incidence and spectrum of dialysis-associated cancer in three continents. Am J Kidney Dis. 2000;35:347-353.
8. Kumar V, Abbus AK, Fausto N. Neoplasia. In: Kumar V, Abbus AK, Fausto N, eds. Robbins and Cotran pathologic basis of disease. 7th ed. Philadelphia, PA: Elsevier Saunders; 2005:269-342.
9. Kuper H, Boffetta F, Adami H-O. Tobacco use and cancer causation: association by tumour type. J Intern Med. 2002;252:206-224.
10. Taylor AE, Shuster S. Skin cancer after renal transplantation: the causal role of azathioprine. Acta Derm Venereol. 1992;72:115-119.
11. Silman AJ, Petrie J, Hazleman B, Evans S. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis. 1998;47:988-992.
12. O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005;309:1871-1874.
13. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681-1691.
14. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124:477-484.
15. Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst. 1995;87:524-530.
16. Khan MA, Travis LB, Lynch CF, et al. p53 mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol Biomarkers Prev. 1998;7:397-403.
17. Marple JT, MacDougall M, Chonko AM. Renal cancer complicating acquired cystic kidney disease. J Am Soc Nephrol. 1994;4:1951-1956.
18. Matson MA, Cohen EP. Acquired cystic kidney disease: occurrence, prevalence, and renal cancers. Medicine. 1990;69:217-226.
19. Sattler TA, Dimitrov T, Hall PW. Relation between Balkan nephropathy and urinary tract tumors. Lancet. 1977;1:278-280.
20. Thon WF, Kliem V, Truss MC, et al. De novo urothelial carcinoma of the upper and lower urinary tract in kidney transplant patients with end-stage analgesic nephropathy. World J Urol. 1995;13:254-261.
21. Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med. 1985;313:292-295.
22. Blohme I, Johansson S. Renal pelvic neoplasms and atypical urothelium in patients with end-stage analgesic nephropathy. Kidney Int. 1981;20:671-675.
23. Schollmeyer P, Bozkurt F. The immune status of the uremic patient: hemodialysis vs CAPD. Clin Nephrol. 1988;30:S37-S40.
24. Goldblum SE, Reed WP. Host defenses and immunologic alterations associated with chronic hemodialysis. Ann Intern Med. 1980;93:597-613.
25. Hoy WE, Cestero RV, Freeman RB. Deficiency of T and B lymphocytes in uremic subjects and partial improvement with maintenance hemodialysis. Nephron. 1978;20:182-188.
26. Peto J. Cancer epidemiology in the last century and the next decade. Nature. 2001;411:390-395.
27. Penn I. Posttransplant malignancies. Transplant Proc. 1999;31:1260-1262.
28. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380-384.
29. Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet. 2000;355:1886-1887.
30. Sheil AG, Disney AP, Mathew TH, Livingston BER, Keogh AM. Lymphoma incidence, cyclosporine, and the evolution and major impact of malignancy following organ transplantation. Transplant Proc. 1997;29:825-827.
31. Vamvakas S, Bahner U, Becker P, Steinle A, Gotz R, Heidland A. Impairment of DNA repair in the course of long-term hemodialysis and under cyclosporine immunosuppression after renal transplantation. Transplant Proc. 1996;28:3468-3473.
32. Malachi T, Zevin D, Gafter U, Chagnac A, Slor H, Levi J. DNA repair and recovery of RNA synthesis in uremic patients. Kidney Int. 1993;44:385-389.
33. Yoshimura S, Suemizu H, Nomoto Y, et al. Plasma glutathione peroxidase deficiency caused by renal dysfunction. Nephron. 1996;73:207-211.
34. Akizawa T, Kinugasa E, Koshikawa S. Increased risk of malignancy and blood-membrane interactions in uraemic patients. Nephrol Dial Transplant. 1994;9:162-164.
35. Lindner A, Farewell VT, Sherrard DJ. High incidence of neoplasia in uremic patients receiving long-term dialysis. Nephron. 1981;27:292-296
36. Bush A, Gabriel R. Cancer in uremic patients. Clin Nephrol. 1984;22:77-81
37. Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS. Increased incidence of malignancy during chronic renal failure. Lancet. 1975;1:883-886.
38. Kinlen LJ, Eastwood JB, Kerr DN, et al. Cancer in patients receiving dialysis. BMJ. 1980;280:1401-1403.
39. Sutherland GA, Glass J, Gabriel R. Increased incidence of malignancy in chronic renal failure. Nephron. 1977;18:182-184.
40. Miach PJ, Dawborn JK, Xipell J. Neoplasia in patients with chronic renal failure on long-term dialysis. Clin Nephrol. 1976;5:101-104.
41. Sheil AG, Flavel S, Disney APS, Mathew TH. Cancer development in patients progressing to dialysis and renal transplantation. Transplant Proc. 1985;17:1685-1688.
42. Inamoto H, Ino Y, Sata K, Ozaki R, Aizawa K, Osawa A. High risk ratio on mortality and characteristics of malignancies in dialysis patients. Clin Exp Dial Apheresis. 1983;7:219-224.
43. Port FK, Ragheb NE, Schwartz AG, Hawthorne VM. Neoplasms in dialysis patients: a population-based study. Am J Kidney Dis. 1989;14:119-123.
44. Kantor AF, Hoover RN, Kinlen LJ, McMullan MR, Fraumeni JF Jr. Cancer in patients receiving long-term dialysis treatment. Am J Epidemiol. 1987;126:370-376.
45. Inamoto H, Ozaki R, Matsuzaki T, Wakui M, Saruta T, Osawa A. Incidence and mortality patterns of malignancy and factors affecting the risk of malignancy in dialysis patients. Nephron. 1991;59:611-617.
46. Iseki K, Osawa A, Fukiyama K. Evidence for increased cancer deaths in chronic dialysis patients. Am J Kidney Dis. 1993;22:308-313.
47. Buccianti G, Maisonneuve P, Ravasi B, Cresseri D, Locatelli F, Boyle P. Cancer among patients on renal replacement therapy: a population-based survey in Lombardy, Italy. Int J Cancer. 1996;66:591-593.
48. Gilbertson DT, Yang CC, Collins AJ. Identifying comorbidities in ESRD patients using administrative data [abstract]. J Am Soc Nephrol Suppl. 2002;S13:623A.
49. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339:799-805.
50. US Renal Data System. USRDS 2002 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2002.
51. Kyllonen L, Salmela K, Pukkala E. Cancer incidence in a kidney-transplanted population. Transpl Int. 2000;13 (Suppl 1):S394-S398.
52. Danpanich E, Kasiske BL. Risk factors for cancer in renal transplant recipients. Transplantation. 1999;68:1859-1864.
53. Gaya SB, Rees AJ, Lechler RI, Williams G, Mason PD. Malignant disease in patients with long-term renal transplants. Transplantation. 1995;59:1705-1709.
54. Foley RN, Herzog CA, Collins AJ. Declining incidence and mortality of cardiovascular disease in older end-stage renal disease patients in the United States, 1987-1997 [abstract]. J Am Soc Nephrol Suppl. 2002;S13:432A-433A.
55. Meier-Kreische H-U, Ojo AO, Port FK, Arndorfer JA, Cibrik DM, Kaplan B. Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol. 2001;12:1293-1296.
56. Oreopoulos DG, Dimkovic N. Geriatric nephrology is coming of age. J Am Soc Nephrol. 2003;14:1099-1101.
57. Tsuchida M, Yamato Y, Aoki T, et al. Complications associated with pulmonary resection in lung cancer patients on dialysis. Ann Thorac Surg. 2001;71:435-438.
58. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999;131:174-181.
59. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther. 2003;18:1071-1081.
60. Chertow GM, Paltiel DA, Owen WF Jr, Lazarus MJ. Cost-effectiveness of cancer screening in end-stage renal disease. Arch Intern Med. 1996;156:1345-1350.
61. Kajbaf S, Nichol G, Zimmerman D. Cancer screening and life expectancy of Canadian patients with kidney failure. Nephrol Dial Transplant. 2002;17:1786-1789.
62. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions: standardizing data on outcomes. N Engl J Med. 1998;339:380-386.
63. Holley JL. Preventive medical screening is not appropriate for many chronic dialysis patients. Semin Dial. 2000;13:369-371.
64. Bargman, JM. Neoplasia in dialysis patients: pathophysiology, epidemiology, and screening. Adv Perit Dial. 2000;16:93-96.
65. LeBrun CJ, Diehl LF, Abbott KC, Welch PG, Yuan CM. Life expectancy benefits of cancer screening in the end-stage renal disease population. Am J Kidney Dis. 2000;35:237-243.
66. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA. 2001;285:2750-2756.
67. US Renal Data System. USRDS 2006 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006
68. Guide to clinical preventive services, 2005: recommendations of the U.S. Preventive Services Task Force. AHRQ Publication No. 05-0570, June 2005. Rockville, MD: Agency for Healthcare Research and Quality; 2005. http://www.ahrq.gov/clinic/pocketgd05/. Accessed Jan 15, 2007.
69. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat database: mortality - all COD, public-use with state, total U.S. (1969-2003), April 2006. Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2006. http://www.seer.cancer.gov/. Accessed Jan 8, 2008 [Underlying mortality data provided by NCHS (http://www.cdc.gov/nchs)].
70. Ko CW, Sonnenberg A. Comparing risks and benefits of colorectal cancer screening in elderly patients. Gastroenterology. 2005;129:1163-1170.
71. ERA-EDTA Registry. ERA-EDTA Registry 2004 annual report. Amsterdam, The Netherlands: Academic Medical Center, Department of Medical Informatics; July 2006.
72. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725-1730.
73. Sarasin FP, Wong JB, Levey AS, Meyer KB. Screening for acquired cystic kidney disease: a decision analytic perspective. Kidney Int. 1995;48:207-219.
74. Ishikawa I, Honda R, Yamada Y, Kakuma T. Renal cell carcinoma detected by screening shows better patient survival than that detected following symptoms in dialysis patients. Ther Apher Dial. 2004;8:468-473.